FluoroPharma Medical, Inc. (OTCQB: FPMI) specializes in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image brain tissue affected by Alzheimer’s disease and agents that could potentially be used for imaging specific cancers. For more information visit the company’s website at www.fluoropharma.com.